High-value research and revenue paths in low Earth orbit
Microgravity and radiation change how cells grow, divide and function. OSPRI turns those effects into practical tools for biomanufacturing, disease research and regenerative medicine, in a market projected at $1T by 2030.
Produce better cell products
- Stem cell production
- Organoid production
- Tissue engineering
- Bioprinting
Model disease faster
- Cancer progression
- Cardiovascular disease
- Neurological disorders
- Immune dysfunction
- Sarcopenia
Develop new therapies
- Drug development
- Personalized medicine
- Understanding aging
- Countermeasures
Four services on a single microgravity-optimized platform
Validated hardware for operators and researchers
Bioreactor modules, automated cell processing & analysis, patented and scalable bioprocessing IP, licensed to commercial LEO destination operators and ISS researchers.
Stem cells, organoids and recombinant proteins
For biopharma and academic clients, offered per experiment or as multi-year supply.
Microgravity-enabled disease models
Cancer, cardiovascular, neurodegenerative and immune-dysfunction models, as fee-for-service or pharma co-development.
Regenerative medicine partnerships
Co-developed stem-cell and cell-free therapies for cancer, cardiovascular and neurodegenerative disease.
From protocol to recovered sample
We provide end-to-end services for the management, integration and operation of space-based science and technology payloads, so your team can focus on the science.
Science and protocol design
Translate your ground protocol into a flight-ready process.
Hardware, safety and vehicle integration
Flight certification of COTS automated hardware and safety documentation.
On-orbit operations and return
Automated culture, in-process analytics, cryogenic handling and sample recovery.